Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | MARK3 | P27448 | 1/20 | 0.33 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.33 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1692228 | 0.86 | BUB1 (0.65) | BUB1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL3445913 | 0.81 | BUB1 (0.60) | BUB1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL6305908 | 0.72 | BUB1 (0.38) | BUB1ACHEGPR119ELANEKDM4E | |
| SCHEMBL24852180 | 0.70 | BUB1 (0.54) | BUB1PIM1PIM2ACHEGPR119 | |
| SCHEMBL6304493 | 0.70 | ALDH1A1 (0.43) | BUB1KDM4EALDH1A1 | |
| SCHEMBL17372467 | 0.68 | BUB1 (1.00) | BUB1ACHEKDM4EALDH1A1 | |
| SCHEMBL20780061 | 0.68 | BUB1 (0.50) | BUB1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL6302508 | 0.68 | KDM4E (0.40) | BUB1KDM4EALDH1A1 | |
| SCHEMBL13477016 | 0.67 | HPGD (0.43) | BUB1ELANEKDM4EALDH1A1PKM | |
| SCHEMBL17498059 | 0.67 | BUB1 (0.47) | BUB1PIM1MARK3MAP4K2CAMK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816536-B2 | enantioselective functionalization at the less reactive 4-position; alkenylation of the 4-(leaving group)-6,7-dihydro ring with an electron-withdrawing vinyldiazo compound using a a dirhodium catalyst; drug intermediate | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070004787-A1 | enantioselective functionalization at the less reactive 4-position; alkenylation of the 4-(leaving group)-6,7-dihydro ring with an electron-withdrawing vinyldiazo compound using a a dirhodium catalyst; drug intermediate | NATIONAL SCIENCE FOUNDATION | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004787-A1 | enantioselective functionalization at the less reactive 4-position; alkenylation of the 4-(leaving group)-6,7-dihydro ring with an electron-withdrawing vinyldiazo compound using a a dirhodium catalyst; drug intermediate | CYP3A4, CYP2D6, CYP3A7 | BUB1 4036/4885PIM1 275/4885MARK3 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.